About Lumos Pharma, Inc. (LUMO) — Dividend Analysis 2026
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Is LUMO a good dividend investment in 2026?
LUMO offers a 46.08% forward yield with a 50% payout ratio. Strand Safety Score: 0/100 (Critical Risk). The 5-year dividend CAGR of 0% is modest — investors should weigh current income against growth alternatives.
LUMO DRIP calculator — what's the difference?
With DRIP on a $10,000 investment over 10 years, your LUMO portfolio grows to $3.50M vs $48.4K without reinvestment. This is the compound interest effect in action.
LUMO dividend growth history & forecast
LUMO has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 46.08%.
Company generates negative FCF ($-31M) — borrowing to pay dividends
Debt Leverage0.0× Debt/EBITDA
0 / 30 pts
0/30
Company not generating EBITDA — debt servicing risk is elevated
Earnings Momentum-0.0B → -0.0B → -0.0B
0 / 30 pts
0/30
Company is reporting net losses — dividend sustainability is in question
OVERALL ASSESSMENT
High risk of dividend cut — weak fundamentals across multiple factors.
STRAND SCORE
0
/100
Strand Safety Score™ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
🌍 LUMO Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold LUMO.
Gross yield
46.08%
Tax rate
15.00%
After-tax yield
39.17%
Real yield (−CPI)
36.37%
Account/Country
Tax Rate
After-tax Yield
Real Yield
$10K Annual Income
🇺🇸 Roth IRA / 401k
0%
46.08%
43.28%
$4,608 / yr
🇺🇸 US Taxable (15%) ✓
15%
39.17%
36.37%
$3,917 / yr
🇺🇸 US Taxable (20%)
20%
36.86%
34.06%
$3,686 / yr
🇬🇧 UK ISA
0%
46.08%
43.28%
$4,608 / yr
🇬🇧 UK Taxable
8.75%
42.05%
39.25%
$4,205 / yr
🇨🇦 TFSA
0%
46.08%
43.28%
$4,608 / yr
🇨🇦 CA Taxable
25%
34.56%
31.76%
$3,456 / yr
🇦🇺 Super (pension)
15%
39.17%
36.37%
$3,917 / yr
🇦🇺 AU Taxable
30%
32.26%
29.46%
$3,226 / yr
🇩🇪 DE Taxable
26.375%
33.93%
31.13%
$3,393 / yr
🇫🇷 FR Taxable
30%
32.26%
29.46%
$3,226 / yr
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 LUMO Income Goal & Break-Even
Dividend Break-Even
3yr
Years for dividends to fully repay your LUMO investment of $4.34/share (🇺🇸 US Taxable (15%) · 15.00% tax)
$10K invested · 10 Years
Dividends earned (DRIP)
$1.76M
Lost to inflation (2.8% CPI)
−$2.5K
Real purchasing power gain
$1.76M
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in LUMO for:
Shares needed
14,118
Capital required
$61,272
Monthly income
$2,000
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 LUMO Dividend Payment Schedule
LUMO pays quarterly — 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
💰
Apr
May
Jun
💰
Jul
Aug
Sep
💰
Oct
Nov
Dec
💰
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
📊 LUMO vs Healthcare Benchmarks
How LUMO compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yield▲+43.28% vs sectorBetter
LUMO
46.08%
avg
2.80%
5Y Dividend CAGR▼-6.80% vs sectorBelow avg
LUMO
0.00%
avg
6.80%
Payout Ratio▲-5.00% vs sectorBetter
LUMO
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for LUMO sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ LUMO Insider Activity
▼ 1 Sales
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
Insider
Title
Type
Date
Shares
Price
Total Value
Pitukcheewanont Pisit Duke
officer: Chief Medical Officer
Other
2024-07-01
25,500
$3.30
$84.2K
Pitukcheewanont Pisit Duke
officer: Chief Medical Officer
Other
2023-06-01
29,750
$7.69
$228.8K
Pitukcheewanont Pisit Duke
officer: Chief Medical Officer
Other
2024-02-01
3,333
$3.52
$11.7K
McKew John C.
officer: Chief Scientific Officer
F-InKind
2023-08-01
1,593
$3.28
$5.2K
McKew John C.
officer: Chief Scientific Officer
Sale
2023-08-02
3,407
$3.21
$10.9K
Lawley Lori D
officer: Chief Financial Officer
F-InKind
2023-08-01
229
$3.28
$751.00
Zoth Lota S.
director
A-Award
2023-05-10
3,345
$3.42
$11.4K
van Es-Johansson An
director
A-Award
2023-05-10
3,345
$3.42
$11.4K
Raffin Thomas A.
director
A-Award
2023-05-10
3,345
$3.42
$11.4K
McCracken Joseph S
director
A-Award
2023-05-10
3,345
$3.42
$11.4K
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
🎯
Analyst Price Target
Wall Street consensus
Current Price
$4.34
Analyst Target
$16.50
Upside / Downside
+280.2%
Range
$7.00 – $26.00
💡 If LUMO reaches the analyst target of $16.50, investors buying today at $4.34 would see an effective yield of 12.12% on shares purchased at target price — vs 46.08% at current price.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
🔬
Financial Health Scores
Altman Z-Score
-19.20
🔴 Distress Zone — elevated dividend cut risk
Safe: >3.0 · Grey: 1.81–3.0 · Distress: <1.81
Piotroski F-Score
3/9
🔴 Weak fundamentals — dividend safety concern
Strong: 7–9 · Moderate: 4–6 · Weak: 0–3
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
📊 About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the LUMO dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →